Companies: 10,795·Total market cap: $144.5T
Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc.

CYTNASDAQHealthcare
$3.02
$-0.07(-2.27%)
Market Cap$108714262
P/E Ratio—
52W High$3.19
52W Low$1.65
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Cyteir Therapeutics, Inc. (CYT) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · CYT · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.87cyt eps ttm · cyt earnings per shareEarnings history
PE Ratio (TTM)—cyt pe ratio ttm · cyt price to earningsPE Ratio deep dive
Revenue (TTM)0.00cyt revenue ttm · cyt annual revenueFull revenue history
Dividend Yield2.99%does cyt pay dividends · cyt dividend yieldDividend history
Shares Outstanding35.3Mcyt shares outstanding · cyt floatShares outstanding history
Next EarningsTBAcyt earnings date · cyt next earningsEarnings history

Explore Cyteir Therapeutics, Inc. Data

cyt stock data · financials
Market Cap$108.7Mcyt market cap · cyt valuation
Analyst Forecast$2 · Buy
Dividends2.99%does cyteir therapeutics, inc. pay dividends · cyt dividend yield
Revenue—cyteir therapeutics, inc. annual revenue · cyt revenue
EarningsEPS $-1.25-5.93%cyt earnings · cyt eps
PE Ratio—cyt pe ratio · cyt price to earnings

Financial Snapshot

Full Financials
FY 2022Revenue$0.00
202020212022
cyteir therapeutics, inc. revenue · cyt revenue 2022
FY 2022Net Income-$44.0M▼ 5.53% YoY
202020212022
cyteir therapeutics, inc. net income · cyt profit 2022
FY 2022EPS$-1.25▼ 5.93% YoY
202020212022
cyt eps · cyteir therapeutics, inc. earnings per share 2022
TTM:Revenue: $0.00Net Income: -$30.9MEPS: $-0.87View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis cyt a buy · cyt analyst rating
Strong Buy
0
Buy
2
Hold
1
Sell
2
Strong Sell
0
12-Month Price Target
$2.00Low
$3.02Current
$2.00Avg Target33.77% downside
$2.00High
cyt price target · cyt 12 month forecast

Total: 5 · Buy rate: 40.0%

The CYT analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $2.00, representing -33.77% downside from the current price of $3.02.

Stock Performance

Full History
1D+0.33%
1W+0.33%
1M-2.27%
3M-2.58%
YTD+0.00%
1Y+55.68%
5Y-82.64%

About Cyteir Therapeutics, Inc.

CEOMarkus F. Renschler
IPO DateJun 18, 2021
Employees46
CountryUS
Websitecyteir.com

Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an no…

BiotechnologyHealthcareNASDAQUS

what is cyteir therapeutics, inc. · cyt stock overview · cyteir therapeutics, inc. company profile · who is cyteir therapeutics, inc. ceo · cyt NASDAQ · cyteir therapeutics, inc. headquarters · cyteir therapeutics, inc. business segments

About Stock Overview & Key Data

Cyteir Therapeutics, Inc. (CYT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 18, 2021. As of the latest trading session, CYT stock price is $3.02, with a market capitalization of $108.7M. The stock has returned +55.68% over the past 12 months and +0.00% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Cyteir Therapeutics, Inc. stock is Buy, with an average 12-month price target of $2.00. In fiscal year 2022, Cyteir Therapeutics, Inc. reported revenue of — and net income of -$44.0M. For detailed data — including Cyteir Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Cyteir Therapeutics, Inc. (CYT) stock price is $3.02. The stock is traded on NASDAQ under the ticker symbol CYT. The 52-week range is $1.65 – $3.19.

CYT stock priceCYT quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice